Zacks Investment Research cut shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a hold rating to a sell rating in a research note published on Friday.
According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
Other analysts also recently issued reports about the stock. Northland Securities began coverage on shares of Adamas Pharmaceuticals in a report on Wednesday, November 29th. They issued an outperform rating for the company. ValuEngine raised shares of Adamas Pharmaceuticals from a sell rating to a hold rating in a report on Friday, February 2nd. Cowen set a $55.00 price target on shares of Adamas Pharmaceuticals and gave the company a buy rating in a report on Wednesday, December 13th. BidaskClub downgraded shares of Adamas Pharmaceuticals from a buy rating to a hold rating in a report on Saturday, February 3rd. Finally, Evercore ISI began coverage on shares of Adamas Pharmaceuticals in a report on Monday, October 30th. They issued an outperform rating for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Adamas Pharmaceuticals presently has an average rating of Buy and a consensus target price of $45.14.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.09). The business had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.84 million. During the same period in the previous year, the business posted ($0.68) earnings per share. Adamas Pharmaceuticals’s revenue for the quarter was up 1435.1% on a year-over-year basis. analysts anticipate that Adamas Pharmaceuticals will post -3.44 earnings per share for the current year.
Several large investors have recently added to or reduced their stakes in the company. Alps Advisors Inc. lifted its holdings in shares of Adamas Pharmaceuticals by 9.9% during the 3rd quarter. Alps Advisors Inc. now owns 22,172 shares of the specialty pharmaceutical company’s stock worth $469,000 after acquiring an additional 1,990 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in shares of Adamas Pharmaceuticals by 11.7% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 30,690 shares of the specialty pharmaceutical company’s stock worth $1,041,000 after acquiring an additional 3,218 shares during the period. EAM Investors LLC lifted its holdings in shares of Adamas Pharmaceuticals by 5.7% during the 4th quarter. EAM Investors LLC now owns 89,585 shares of the specialty pharmaceutical company’s stock worth $3,036,000 after acquiring an additional 4,792 shares during the period. SG Americas Securities LLC bought a new position in shares of Adamas Pharmaceuticals during the 3rd quarter worth about $110,000. Finally, Quantbot Technologies LP bought a new position in shares of Adamas Pharmaceuticals during the 3rd quarter worth about $119,000. 66.90% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3224869/zacks-investment-research-downgrades-adamas-pharmaceuticals-adms-to-sell.html.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.